Hospitalization for pneumothorax compared with date of BHD diagnosis.

The figure shows the onset and in-hospital period for pneumothorax per patient. The month zero is defined by the day of BHD diagnosis, and the shaded area is the previous 3 months of the diagnosis. The hospital admission period is depicted as the length of each bar.</p

Number of pneumothoraxes among BHD patients.

Number of pneumothoraxes among BHD patients.</p

Associated malignancy in patients with BHD syndrome before and after folliculin gene test.

Associated malignancy in patients with BHD syndrome before and after folliculin gene test.</p

Diseases included in rare incurable disease code.

NA: not applicable due to absence of a defined code. (DOCX)</p

Tests included in C5808 codes.

(DOCX)</p

The number of BHD patients according to age group and sex.

The number of BHD patients according to age group and sex.</p

Associated diseases before and after the diagnosis of BHD syndrome.

Associated diseases before and after the diagnosis of BHD syndrome.</p

Additional file 2 of Comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia

Additional file 2. Primary and secondary outcomes of both groups according to the pneumonia type. CAP community-acquired pneumonia, HAP hospital-acquired pneumonia, VAP ventilator-associated pneumonia

Additional file 3 of Comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia

Additional file 3. Primary and secondary outcomes of the low-dose and high-dose teicoplanin groups. We performed the subgroup analysis between the low-dose and high-dose teicoplanin groups. There was no difference of treatment outcome between the two groups. Additionally, we performed univariate and multivariate analysis with Cox proportional hazard model. All covariates included in Table 3 were included. High-dose teicoplanin presented an odds ratio of 0.649 (95% confidence interval 0.295–1.429, p = 0.283) in univariate analysis and 0.641 (95% confidence interval 0.243–1.690, p = 0.369) in multivariate analysis

Additional file 1 of Comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia

Additional file 1. Primary and secondary outcomes in both groups after excluding patients in whom the study drug was changed because of side effects